Atopic Dermatitis and Keratoconjunctivitis - 11/08/11

Doi : 10.1016/j.iac.2010.06.004

Brett Bielory, MD ^a, Leonard Bielory, MD ^b,^c,^⁎
^a Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136, USA
^b STARx Allergy and Asthma Center, 400 Mountain Avenue, Springfield, NJ 07081, USA
^c Center for Environmental Prediction, Rutgers University, 14 College Farm Road, New Brunswick, NJ 08901–8551, USA

Corresponding author. STARx Allergy and Asthma Center, 400 Mountain Avenue, Springfield, NJ 07081.

Résumé

Atopic dermatitis, a chronic disease seen by allergist-immunologists, has both dermatologic and ocular manifestations. The ocular component is often disproportionately higher than the dermatologic disease. Even if skin abnormalities seem well controlled, these patients require ophthalmic evaluation. Atopic keratoconjunctivitis in atopic dermatitis patients is characterized by acute exacerbations and requires maintenance therapy for long-term control. Future studies will continue to emphasize the use of steroid-sparing, immunomodulating agents that have the potential to provide long-lasting anti-inflammatory control with a more favorable side-effect profile.

Le texte complet de cet article est disponible en PDF.

Keywords : Atopic dermatitis, Atopic keratoconjunctivitis, Ocular allergy, Blepharoconjunctivitis, Keratoconus

Plan

Immunopathophysiology

Clinical manifestations

Epidemiology and Concomitant Disorders

Complications

Nasal-ocular links in AKC

Treatment

Summary

Financial disclosures: B. Bielory has nothing to disclose. L. Bielory has received financial support from Schering-Plough, Glaxo-Smith-Kline, Merck, Otsuka, Novartis, Sanofi-Aventis, Genentech, Astellas, UCB-Pharma, Alcon, Meda, Inspire, Santen, Allergan, ISTA, SARCode, Bausch and Lomb, Vistakon, ViroPharm, Dyax, Jerini, Ocusense (Tear Lab), and Rutgers University Press. No funding support was provided for the development of this article.